Halozyme Therapeutics reported $2.15B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amarin USD 0 0 Mar/2025
Amgen USD 57.3B 19M Jun/2026
Baxter International USD 9.67B 20M Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 1.27B 18.17M Jun/2026
DBV Technologies USD 7.5M 1.4M Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
MannKind USD 330.85M 112K Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 62.67B 523M Sep/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024